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Abstract
Rationale Dopamine stabilizers have stimulatory actions un-
der low dopamine tone and inhibitory actions under high do-
pamine tone without eliciting catalepsy. These compounds are
dopamine D2 receptor (D2R) antagonists or weak partial ago-
nists and may have pro-mnemonic and neuroprotective ef-
fects. The mechanism underlying their stimulatory and neuro-
protective actions is unknown but could involve sigma-1R
binding.
Objectives The present study examined sigma-1R and D2R
occupancy by the dopamine stabilizer pridopidine (ACR16)
at behaviorally relevant doses in living rats.
Methods Rats were administered 3 or 15 mg/kg pridopidine,
or saline, before injection of the radiotracer 11C-SA4503
(sigma-1R) or 11C-raclopride (D2R). Some animals received
60 mg/kg pridopidine and were only scanned with 11C-
raclopride. Cerebral 11C-SA4503 binding was quantified
using metabolite-corrected plasma input data and distribution
volume (VT) calculated by Logan graphical analysis.
11C-
raclopride binding was quantified using striatum-to-
cerebellum ratios and binding potentials calculated with a
simplified reference tissue model.
Results Cunningham-Lassen plots indicated sigma-1R occu-
pancies of 57±2 and 85±2 % after pretreatment of animals
with 3 and 15 mg/kg pridopidine. A significant (44–66 %)
reduction of 11C-raclopride binding was only observed at
60 mg/kg pridopidine.
Conclusions At doses shown to elicit neurochemical and be-
havioral effects, pridopidine occupied a large fraction of
sigma-1Rs and a negligible fraction of D2Rs. Significant
D2R occupancy was only observed at a dose 20-fold higher
than was required for sigma-1R occupancy. The characteris-
tics of dopamine stabilizers may result from the combination
of high sigma-1R and low D2R affinity.
Keywords MicroPET . Kinetic analysis . 11C-SA4503 .
11C-raclopride . Receptor occupancy
Introduction
Pridopidine (also known as ACR16 or Huntexil) is a
phenylpiperidine compound undergoing clinical trials for
treatment of motor symptoms in Huntington’s disease (de
Yebenes et al. 2011; Kieburtz et al. 2013; for the ongoing
Pride-HD trial, see NCT02006472 at clinicaltrials.gov).
Moreover, pridopidine has shown promising results in limited
trials for schizophrenia and Parkinson’s disease (Ponten et al.
2010). The drug displays micromolar affinity for the dopa-
mine D2 receptor (D2R), where it acts as an antagonist
(Dyhring et al. 2010; Sahlholm et al. 2014) or very weak
partial agonist (Seeman et al. 2009; Kara et al. 2010).
P r idop id ine an tagon izes amphe tamine - induced
hyperlocomotion (Natesan et al. 2006; Ponten et al. 2010)
and reduces L-DOPA-induced locomotor sensitization in 6-
hydroxydopamine-lesioned rats (Ponten et al. 2013). Howev-
er, even at doses resulting in near-complete D2R occupancy
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(assessed using ex vivo radioligand binding), pridopidine
shows very low propensity for inducing catalepsy (Natesan
et al. 2006). Furthermore, pridopidine stimulates locomotor
activity in habituated animals showing low baseline locomo-
tor activity (Rung et al. 2008) and increases dopamine release
in several brain regions including the prefrontal cortex
(Ponten et al. 2010). Based on these properties, pridopidine
and structurally related compounds showing similar in vivo
efficacy such as (−)-OSU6162 have been termed “dopamine
stabilizers” as they exhibit inhibitory or stimulatory effects on
dopamine-dependent behavior depending on the prevailing
dopamine tone (Ponten et al. 2010).
(−)-OSU6162 displays higher in vitro affinity for D2R than
pridopidine (Pettersson et al. 2010). Interestingly however,
while (−)-OSU6162 was more potent in raising serum prolac-
tin and in producing D2R occupancy, pridopidine was more
potent in inhibiting amphetamine-induced hyperlocomotion
(Natesan et al. 2006). Moreover, pridopidine showed pro-
cognitive and pro-social effects, which are not typical of
D2R ligands, in animal models of cognitive and negative
symptoms of schizophrenia and in scopolamine-induced am-
nesia (Rung et al. 2005; Nilsson and Carlsson 2013). Further-
more, the abilities of haloperidol and (−)-OSU6162 to coun-
teract amphetamine-induced hyperlocomotion were abolished
in D2R knockout mice, whereas the effects of pridopidine
persisted (Svensson et al. 2009). Based on the induction of
the immediate-early gene Arc (a marker of synaptic activity)
by pridopidine in prefrontal cortex, which again is not ob-
served wi th other D2R antagonis ts or agonis ts ,
nondopaminergic effects of pridopidine have been postulated,
which would involve an increase in cortical N-methyl-D-as-
partate (NMDA) receptor activity (Ponten et al. 2010; Waters
et al. 2014). Finally, neuroprotective effects of pridopidine and
(−)-OSU6162 have recently been described in in vitro and
in vivo models of Huntington’s disease (Ruiz et al. 2012;
DiPardo et al. 2013). Taken together, the present literature
findings suggest additional sites of action for pridopidine be-
sides D2R, and as detailed below, we have considered the
sigma-1 receptor (sigma-1R) as such an additional target.
The sigma-1R is a two-transmembrane protein that is wide-
ly expressed in the brain and has been implicated mainly in
regulation of synaptic strength and cell survival. Sigma-1R
lacks homology to any knownmammalian protein, is believed
to function both as an ER chaperone and as a co-receptor for a
variety of other transmembrane proteins, and has been shown
to modulate voltage-gated ion channels, NMDA receptors,
and dopamine receptors (Maurice and Su 2009; Navarro
et al. 2010; van Waarde et al. 2011). The sigma-1R is known
to bind the endogenous steroids dehydroepiandrosterone-
sulfate and progesterone and the hallucinogenic trace amine,
N,N-dimethyltryptamine, along with exogenous substances
such as cocaine and haloperidol (Fontanilla et al. 2009). On
basis of the actions of its ligands in animal models, sigma-1R
is considered as a pharmacological target for the treatment of
Parkinson’s disease (including L-DOPA-induced dyskinesia),
Alzheimer’s disease, schizophrenia, and drug addiction
(Guitart et al. 2004; Maurice and Su 2009; van Waarde
et al. 2011).
In radioligand competition experiments using 3H-(+)-pen-
tazocine, pridopidine and (−)-OSU6162 were recently found
to display nanomolar affinity for the sigma-1R (Sahlholm
et al. 2013). For pridopidine, the observed affinity for sigma-
1R was about 100-fold higher than that reported for D2R
(high-affinity Ki about 70 nM at sigma-1R and 7520 nM at
D2R), while (−)-OSU6162 showed only about two times
higher affinity for sigma-1R than for D2R (high-affinity Ki
about 360 nM at sigma-1R and 760 nM at D2R; Sahlholm
et al. 2013; Pettersson et al. 2010). As detailed above, the
effects of some sigma-1R ligands are similar to the actions
of dopamine stabilizers that cannot easily be attributed to
D2R antagonism. Therefore, we examined the occupancies
of sigma-1R and D2R by pridopidine in the living rat brain.
Pridopidine was administered at the lower end of the active
dose range, as determined in previous behavioral and neuro-
chemical studies, in order to assess a putative selective occu-




11C-raclopride was prepared by 11C-methyl-
ation of its hydroxy precursor (Farde et al. 1988). The tracer
was dissolved in sterile saline. Specific radioactivity was
>10 GBq/μmol at the time of injection. The sigma-R ligand
1 - [ 2 - ( 3 , 4 - d i m e t h o x y p h e n e t h y l ) ] - 4 - ( 3 -
phenylpropyl)piperazine (11C-SA4503) was produced by 11C-
methylation of 4-O-demethyl SA4503 (Kawamura et al.
2003). The isotonic tracer solution had a pH of 6.0 to 7.0, a
specific radioactivity >15 GBq/μmol at the moment of injec-
tion, and a radiochemical purity >98 %. Pridopidine hydro-
chloride (ACR16) was custom synthesized by Axon
MedChem BV (Groningen, Netherlands). HPLC grade etha-
nol was from Merck (Darmstadt, Germany), and methanol
and acetonitrile were purchased from Rathburn (Walkerburn,
Scotland).
Animals
Male Wistar Unilever rats were obtained from Harlan
(Boxmeer, Netherlands). The animals were housed in
Makrolon cages on a layer of wood shavings at constant tem-
perature (21±2 °C) and a 12-to-12 h light-dark regimen. They
were fed standard laboratory chow (RMH-B, Hope Farms,
The Netherlands) and received food and water ad libitum.
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The rats were allowed to acclimate for at least 7 days after they
had been transported to Groningen. The research protocol was
approved by the Institutional Animal Care and Use Commit-
tee of Groningen University (file no. 6867A). All experiments
were performed by licensed investigators in compliance with
the Law on Animal Experiments of The Netherlands.
Drug dosing and blood sampling
Saline or pridopidine dissolved in saline (3, 15, or 60 mg/kg,
s.c.) was administered to awake rats 60 min before tracer
injection. Data of the animals (body weight, injected tracer
dose, number of subjects in each dose group) are listed in
Table 1. Animals were first scanned with 11C-raclopride and
subsequently with 11C-SA4503, after an interval of at least
1 week, with exception of the animals that received 60 mg/kg
pridopidine. Because of limited availability of the test drug,
the 60 mg/kg dose group was scanned only with 11C-
raclopride.
After drug administration and about 20 min before each
microPET scan, animals were anesthetized with isoflurane
(Pharmachemie BV, Haarlem, Netherlands). A tail vein can-
nula was placed in each rat for injection of 11C-raclopride and
a femoral vein cannula for injection of 11C-SA4503. In the
case of 11C-SA4503 scans, a femoral artery cannula was also
placed for blood sampling and determination of the time
course of radioactivity in plasma, as described previously
(Ramakrishnan et al. 2014). Both tracers were injected as a
slow bolus (1 ml of saline-diluted tracer solution infused dur-
ing a period of 1 min), using a Harvard-style injection pump.
By the use of a pump, inter-individual variability in the
outcome parameters of kinetic modeling is reduced
(Visser et al. 2013).
From each animal used for kinetic modeling
(Table 1), 15 arterial blood samples (volume 0.1 to
0.15 ml) were drawn at 0.17, 0.33, 0.5, 0.67, 0.83, 1,
1.5, 2, 3, 5, 7.5, 10, 15, 30, and 60 min after 11C-
SA4503 injection and the start of the microPET scan.
From these samples, 25 μl of whole blood was collect-
ed and plasma (25 μl) was then obtained by centrifuga-
tion of the remaining sample (5 min at 13,000×g). Ra-
dioactivity in plasma and whole blood was determined
using a calibrated gamma counter (CompuGamma
CS1282, LKB-Wallac, Turku, Finland). Results are
expressed as standardized uptake values (SUV), defined
as [(plasma activity concentration (MBq/g) × body
weight (g) / injected dose (MBq)]. Rat plasma was as-
sumed to have a specific gravity of 1 g/ml.
Separate animals were used for analysis of tracer metabo-
lites in plasma. In these rats, five arterial blood samples were
collected at 5, 10, 20, 40, and 60 min. Plasma was obtained
from these samples by centrifugation (2 min at 13,000×g).
One volume of plasma was mixed with one volume of a 1:1
mixture of 20 % trichloroacetic acid and acetonitrile. Proteins
were precipitated by centrifugation (2 min at 13,000×g). The
clear supernatant was injected in a reversed-phase HPLC sys-
tem to separate parent tracer and metabolites. An Alltima C18
column (250×10 mm, 5 μ) was used; the mobile phase
consisted of 100 mM NaH2PO4/ethanol 55:45 (v/v) at a flow
rate of 3 ml/min. The eluate was collected in 20-s fractions for
12 min, and radioactivity in the fractions was measured using
a gamma counter. Retention time of authentic 11C-SA4503
was 7.5 min whereas two metabolites were eluted at retention
Table 1 Data concerning the experimental animals (body weights, injected doses, group sizes)
Data concerning 11C-raclopride scans
Pridopidine dose (mg kg) Body weight at scan date (g) 11C-raclopride injected (MBq) Number of animals (N)
0 315±5 37±4 4
3 339±19 23±5 5
15 316±10 22±5 4
60 350±9 25±1 2
Data concerning 11C-SA4503 scans
Pridopidine dose (mg kg) Body weight at scan date (g) 11C-SA4503 injected (MBq) Number of animals (N)
0 354±28 15±5 4
3 372±23 13±3 4
15 346±10 11±4 4
Data concerning 11C-SA4503 metabolite assays
Pridopidine dose (mg kg) Body weight at scan date (g) 11C-SA4503 injected (MBq) Number of animals (N)
0 301±17 24±3 2
3 366±79 33±6 2
15 336±28 23±4 2
Body weights and injected doses are listed as mean±SEM
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times of 4.3 and 6.3 min. The areas under the radioactive
peaks were calculated, and results were expressed as the frac-
tion of plasma radioactivity representing parent tracer (in %).
MicroPET scans
Two rats were scanned in each scan session. They were posi-
tioned on heating mats in a microPET Focus 220 system, in
transaxial position above each other with their brains in the
field of view. Body temperature of the animals was kept close
to normal with electronic temperature controllers. Heart rate
and oxygen level of the blood during the scan were monitored
using pulse oximeters (PulseSense, Nonin). A transmission
scan (duration 515 s) with a Co-57 point source was first
made, in order to correct the subsequently acquired emission
data for attenuation and scatter of 511 keV photons. The first
rat was injected with tracer (11C-raclopride or 11C-SA4503)
simultaneously with the start of the acquisition of emission
data by the PET camera, whereas the second animal was
injected 16 min later. A list mode protocol was used with a
76-min acquisition time.
Image reconstruction was performed using microPET
Manager 2.3.3.6 (Siemens). The PET data were split accord-
ing to position along the y-axis, so that a separate data set was
acquired for each animal. The list mode data of the emission
scans were reframed in a dynamic sequence of 6×10, 4×30,
2×60, 1×120, 1×180, 4×300, and 3×600 s (with an addi-
tional 960-s frame for the rat that was injected first). The data
were reconstructed per time frame employing an iterative re-
construction algorithm (OSEM2D with Fourier rebinning, 4
iterations, and 16 subsets). The final datasets consisted of 95
slices with a slice thickness of 0.8 mm and an in-plane image
matrix of 128×128 pixels. Data sets were corrected for decay,
random coincidences, scatter, and attenuation.
Data analysis
In 11C-raclopride scans of the brain, three-dimensional regions
of interest (ROIs) were manually drawn over the left and right
striatum and cerebellum, using the program ASIPro 6.3.3.0
(Siemens). Each ROI had a standard size of 50 μl. Time-
activity curves (TACs) were generated for these regions
(Fig. 1). The results are expressed as dimensionless standard-
ized uptake values (PET-SUV), defined as [(tissue activity
concentration (MBq/g) × body weight (g) / injected dose
(MBq)]. Brain tissue was assumed to have a specific gravity
of 1 g/ml.
Time-dependent striatum-to-cerebellum ratios of radioac-
tivity were calculated from these TACs, and a first-order rate
equation was fitted to these data (Fig. 2a). Plateau values for
the striatum-to-cerebellum ratio were derived from this curve
fit. A simplified reference tissue model (Lammertsma and
Hume 1996) was also fitted to the striatal TACs, using cere-
bellum as reference.
PET images for 11C-SA4503 were co-registered with an
MRI template using the program PMOD (PMOD Technolo-
gies Ltd, Zürich, Switzerland), and three-dimensional ROIs
for individual brain regions were copied from MRI to PET
as described previously (Ramakrishnan et al. 2014). Logan
graphical analysis was used to calculate regional tracer distri-
bution volumes (VT). The starting time of the Logan fit was
20 min. Metabolite-corrected plasma radioactivity data were
used as input function, and (uncorrected) whole blood radio-
activity served to estimate the contribution of blood to brain
radioactivity measured by the PET camera. The plasma time-
activity curve (TAC) of each animal was corrected for
Fig. 1 Time-activity curves of the dopamine D2 receptor ligand
11C-
raclopride in rat striatum (Str) and cerebellum (Cer) after treatment of
animals with 3 (a), 15 (b), or 60 mg/kg pridopidine (c). Data are plotted
as mean±SEM
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metabolites using an exponential function obtained from the
average metabolite curve of rats which had received the same
dose of pridopidine. The PMOD software package was used
for curve fitting. A Cunningham-Lassen plot (Lassen et al.
1995; Cunningham et al. 2010) was made to estimate
r e cep to r occupancy, a s desc r i bed p r ev ious ly
(Ramakrishnan et al. 2014).
Statistics
Differences between AUCs were examined using the t
test. The biodistribution, VT and BP data were analyzed
using ANOVA. A post hoc Bonferroni test was done
when applicable. P values <0.05 were considered statis-
tically significant.
Results
11C-raclopride kinetics in brain
The D2R ligand
11C-raclopride entered the brain within
3 min and was washed out more rapidly from the ref-
erence region (cerebellum) than the target region
(striatum) (Fig. 1a). Pretreatment of animals with
pridopidine had a dose-dependent effect on the 11C-
raclopride time-activity curves. At the lowest dose test-
ed (3 mg/kg), pridopidine appeared to increase tracer
uptake in striatum but not in cerebellum (Fig. 1a).
When the pridopidine dose was raised to 15 mg/kg,
the drug appeared to increase tracer uptake in both stri-
atum and cerebellum to a rather minor extent (Fig. 1b).
Administration of 60 mg/kg pridopidine resulted in a
striking increase of the uptake of 11C-raclopride in both
striatum and cerebellum (Fig. 1c). The relative increase
in striatum (compared to uptake at baseline) was smaller
than the relative increase in cerebellum.
Target-to-nontarget ratios of 11C-raclopride
In the brain of animals scanned with 11C-raclopride,
striatum-to-cerebellum ratios of radioactivity rose to a
plateau value which was reached after a time interval
ranging from 15 to 60 min, depending on the adminis-
tered pridopidine dose (Fig. 2a). The level of this pla-
teau could be estimated by fitting a first-order rate
equation to the PET data. After administration of a
low dose of pridopidine (3 mg/kg), the plateau value
appeared to be increased (Fig. 2). A higher pridopidine
dose (15 mg/kg) produced a slight decrease of the level
of the plateau (Fig. 2). Particularly, the lowest dose of
pridopidine increased the inter-individual variability in
the kinetics of 11C-raclopride in striata; for this reason,
neither the effect of 3 mg/kg nor that of 15 mg/kg
pridopidine on the level of the plateau was statistically
significant (Fig. 2). Administration of 60 mg/kg
pridopidine resulted in a significant decrease of the
target-to-nontarget ratio of 11C-raclopride (Fig. 2). Tar-
get binding of the radioligand (striatum-to-cerebellum
ratio at plateau minus one) was reduced from 2.85±
0.48 at baseline to 0.96±0.10 by 60 mg/kg pridopidine
(mean±S.D., P<0.01, Fig. 2b), corresponding to a D2R
occupancy of 66 %.
A simplified reference tissue model (SRTM) could be fitted
to the PET data of 11C-raclopride, using striatum as the target
region and cerebellum as the reference region. Binding poten-
tial values calculated with the SRTM demonstrated similar
drug-induced changes as striatum-to-cerebellum ratios
(Fig. 2c). However, D2R occupancy by pridopidine at
60 mg/kg calculated from the SRTM fit was lower than values
Fig. 2 Time-dependent striatum-to-cerebellum ratios of radioactivity (a),
plateau levels of these ratios minus one (b), and binding potential values
for 11C-raclopride in rat striatum calculated with a simplified reference
tissue model (c). Data are plotted as mean±SEM
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calculated using the striatum-to-cerebellum ratio (44 vs. 66%,
respectively; see Figs. 2c, b).
11C-SA4503 kinetics in brain and plasma
Uptake of the sigma-1 receptor ligand 11C-SA4503 in the
brain was rapid (Fig. 3a). A maximum was reached within
the first 5 min after tracer injection and was followed by
washout. The rate of this washout was increased after
pridopidine treatment, and cerebral binding of the ligand
was dose-dependently reduced (Fig. 3a). The area under the
brain time-activity curve (AUC) was significantly decreased
by pridopidine, at both 3 and 15mg/kg (P <0.02 and <0.0005,
respectively, Fig. 3b).
Pretreatment of animals with 3 mg/kg pridopidine had very
little impact on the clearance of 11C-SA4503-derived radioac-
tivity from plasma (Fig. 4a). However, after treatment of ani-
mals with 15 mg/kg pridopidine, the shape of the plasma
curve was altered (Fig. 4b). Compared to untreated controls,
plasma levels of radioactivity were initially reduced (during
the first 5 min after tracer injection) but subsequently in-
creased (between 10 and 60 min). SUV values in Fig. 4 are
plotted on a logarithmic x-axis in order to avoid that all data
points from the initial frames would overlap. Since AUC takes
frame length into account, a small change of radioactivity in a
late frame has more impact on the calculated area than a con-
siderable change in an early frame. The area under the plasma
curve tended to be increased after pridopidine treatment, by 5
and 33 % at doses of 3 and 15 mg/kg, respectively (Fig. 4c).
However, neither of these changes were statistically
significant.
Impact of pridopidine on 11C-SA4503 metabolism
Tracer metabolism was dose-dependently accelerated after
treatment of rats with various doses of pridopidine (Fig. 5).
While 55% of the parent tracer remained unchanged at 60min
in saline-treated rats, only 39 and 33 % remained in the 3 and
15 mg/kg groups.
Fig. 3 Time-activity curves of the sigma-1 receptor ligand 11C-SA4503
in the entire rat brain (a) and areas under the cerebral time-activity activity
curve (b). Data are plotted as mean±SEM
Fig. 4 Time-activity curves of radioactivity in rat plasma after injection
of the sigma-1 receptor ligand 11C-SA4503 (a, b; note logarithmic x-axis)
and areas under the plasma time-activity curve (c). Data are plotted as
mean±SEM
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Kinetic analysis and sigma-1 receptor occupancy
Logan graphical analysis was performed to estimate VT in the
whole brain and in different brain regions. Increasing doses of
pridopidine produced a dose-dependent reduction in VT for all
regions investigated (Fig. 6a). The reduction was statistically
significant at either dose. The Lassen plot as modified by
Cunningham was used to estimate receptor occupancy and
VND (Fig. 6b). Receptor occupancy was 56.7±2.3 % at
3 mg/kg and 84.5±1.7 % at 15 mg/kg. The VND calculated
as an average of the two doses administered was 3.99. Since
the average whole brain VT (after metabolite correction) was
14.39, the specific binding fraction of 11C-SA4503 in rat brain
was >72 %, very similar to the value of 75 % previously
reported using the same method in Wistar-Hannover rats
(Ramakrishnan et al. 2014).
Biodistribution data
Biodistribution data for 11C-SA4503-derived radioactivity are
listed in Table 2. Pridopidine reduced radioligand uptake in
the brain, large intestine, and kidney. However, the plasma
SUV was significantly increased in the 15 mg/kg dose group.
Therefore, tissue-to-plasma ratios of radioactivity provide
more information about the drug effect than raw SUV values.
Dose-dependent reductions of these ratios were observed in all
studied areas of the brain, the kidney, and the spleen. In some
other tissues (adrenal gland, bone marrow, large and small
intestine, lung), reductions were noted only after administra-
tion of the high (15 mg/kg) dose of pridopidine. Drug effects
on tissue-to-plasma ratios in liver and pituitary gland did not
reach statistical significance.
Discussion
The 3 and 15 mg/kg subcutaneous pridopidine doses used in
the present study were chosen since they are at the lower end
of the dose range known to produce neurochemical and be-
havioral effects in rats, e.g., 1.7 mg/kg increased dopamine
release in striatum (Ponten et al. 2010), 7.9 mg/kg decreased
L -DOPA- i ndu c ed r o t a t i o n a l a s ymme t r y i n 6 -
hydroxydopamine-hemilesioned rats (Ponten et al. 2013),
10 mg/kg induced Arc gene expression in frontal cortex (Wa-
ters et al. 2014), and 15.9 mg/kg decreased MK-801- and
amphetamine-induced hyperlocomotion and increased loco-
motor activity in habituated rats (Rung et al. 2008; Ponten
et al. 2010).
No significant changes in 11C-raclopride binding were ob-
served following treatment with 3 and 15 mg/kg pridopidine.
Curiously however, there was a trend for increased 11C-
raclopride binding at 3 mg/kg, along with an increase in the
variability of radiotracer binding between animals. The mech-
anisms behind these effects are unclear but could potentially
involve sigma-1R-mediated alterations of D2R expression or
binding properties, since D2R and sigma-1R have been shown
to form heteromers in striatum (Navarro et al. 2013). Based on
published ex vivo data (Natesan et al. 2006), we expected to
detect substantial D2R occupancy at 15 mg/kg. Since we did
not observe a significant decrease in 11C-raclopride binding at
this dose, we evaluated 60 mg/kg in two additional animals to
confirm D2R binding by pridopidine using in vivo PET. In-
deed, at this elevated dose, a D2R occupancy of 66 or 44% (as
determined using the striatum-to-cerebellum ratio or SRTM
methods, respectively) was observed. Binding potential (BP)
Fig. 5 Fraction of plasma radioactivity representing intact parent
compound after injection of 11C-SA4503. Each data point represents
the mean value of two rats
Fig. 6 Total distribution volume (VT) of
11C-SA4503 in different brain
regions estimated using Logan graphical analysis (a) and Cunningham-
Lassen plot of sigma-1 receptor occupancy by pridopidine (b). Each data
point in the plot represents an individual brain region
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data calculated from the SRTM fit are probably the most reli-
able, since data from the ratio method can deviate from the
true BP values, depending on the kinetics of tracer clearance
from plasma and tissue. Our SRTM data correspond closely to
BP values reported earlier by Lammertsma and Hume (1996).
Particularly at 60 mg/kg, pridopidine seemed to increase the
levels of 11C-raclopride in rat plasma, resulting in increased
nondisplaceable binding of the tracer throughout the brain
(Fig. 1c).
The results of the present study are somewhat divergent
from those of Natesan et al. 2006, who observed substantial
D2R occupancy (35 %) at 10 mg/kg and an ED50 of
18.99 mg/kg. The use of different methodology (in vivo
PET vs. ex vivo radioligand binding) and/or different strains
of rats (Wistar Unilever vs. Sprague-Dawley) may partially
explain the differences in the results obtained. Moreover,
isoflurane anaesthesia, which may inhibit dopamine release
(Westphalen et al. 2013), was used during in vivo PET record-
ings but not in the previous study. Therefore, the larger
pridopidine-induced decreases in 3H-raclopride binding ob-
served by Natesan et al. (2006) may have been produced both
by increases of dopamine release and by occupancy of D2R by
pridopidine. However, other researchers have reported that the
sensitivity of 3H-raclopride binding to amphetamine-induced
dopamine release was not significantly affected by isoflurane
(McCormick et al. 2011).
Pridopidine was administered s.c. since this route of admin-
istration was used in the occupancy study by Natesan et al.
(2006), as well as in the majority of behavioral studies cited in
the present work. It could be argued that pridopidine uptake in
brain may be submaximal 1 h after s.c. administration, due to
slow redistribution from the injection site, resulting in under-
estimation of D2R occupancy. However, time course data re-
ported by Natesan et al. (2006) suggest that maximal D2R
occupancy is reached already within 1 h after s.c. injection
and is maintained for 4 h. It could also be argued that different
radiotracer affinities may have biased the present results. The
affinities of 11C-raclopride and 11C-SA4503 for their respec-
tive targets are not very different (Kds in rat brain tissue of 1.2
and 4.5 nM, respectively; Köhler et al. 1985; Ishiwata et al.
2003). Furthermore, at the tracer doses used in PET, radiotrac-
er affinity should not affect occupancy measurements when
the competitor (pridopidine in this case) is present at constant
levels (Laruelle 2000). Considering the time course data cited
above, the assumption of constant competitor levels seems
reasonable.
Human occupancy data for pridopidine have not yet been
reported, but a recent 11C-raclopride study (Tolboom et al.
2015) examined D2R occupancy by (−)-OSU6162 and ob-
served a 2 to 33 % occupancy in human subjects that received
doses ranging from 15 to 90 mg (between 0.14 and
1.25 mg/kg). Since the dose-occupancy curve appeared to
level off at 40 %, the authors suggested that (−)-OSU6162
Table 2 Biodistribution data of 11C-SA4503 in the various treatment
groups
Tissue Baseline 3 mg/kg 15 mg/kg
Uptake of radioactivity (SUV values), 80 min after injection of 11C-SA4503
Cerebellum 1.95±0.12 0.76±0.17*** 0.73±0.03***
Cerebral cortex 1.97±0.15 1.17±0.17* 0.87±0.05**
Rest brain 2.23±0.31 1.10±0.05* 0.65±0.03*
Adipose tissue 0.26±0.05 0.27±0.06 0.36±0.04
Adrenal gland 25.7±3.6 23.0±4.1 10.7±4.1
Bladder 0.70±0.10 0.88±0.38 0.83±0.22
Bone 0.44±0.14 0.26±0.03 0.44±0.05
Bone marrow 2.57±0.47 2.62±0.67 2.20±0.77
Heart 0.33±0.04 0.23±0.01 0.38±0.02
Intestine (large) 1.72±0.13 1.21±0.12* 0.74±0.08***
Intestine (small) 2.33±0.28 1.93±0.40 1.70±0.15
Kidney 4.19±0.20 2.10±0.09*** 2.07±0.15***
Liver 6.47±0.63 7.71±0.89 7.21±0.83
Lung 1.98±0.18 1.05±0.06* 1.47±0.04
Muscle 0.15±0.02 0.13±0.01 0.22±0.02*
Pancreas 4.95±0.74 5.02±0.64 6.23±0.53
Pituitary 3.24±0.03 2.13±0.44 2.75±0.72
Plasma 0.11±0.02 0.14±0.02 0.28±0.02***
Red blood cells 0.10±0.03 0.07±0.01 0.16±0.01
Spleen 2.62±0.27 2.03±0.12 1.99±0.07
Submandibular gland 3.60±0.18 4.48±0.64 5.77±0.39
Urine 0.35±0.16 1.60±0.87 0.50±0.09
Tissue-to-plasma ratios of radioactivity, 80 min after injection of 11C-SA4503
Cerebellum 20.0±2.8 5.9±1.5** 2.7±0.3**
Cerebral cortex 20.1±2.9 9.0±1.7* 3.2±0.3**
Rest brain 22.0±2.1 8.4±1.3*** 2.4±0.2***
Adipose tissue 2.6±0.5 1.8±0.2 1.3±0.1
Adrenal gland 186±13 184±49 38±14***
Bladder 7.7±2.0 6.9±3.4 3.2±1.0
Bone 4.0±0.8 2.1±0.4 1.6±0.2
Bone marrow 20.6±2.6 21.3±8.1 8.6±3.4*
Heart 3.4±0.7 1.7±0.2 1.4±0.1
Intestine (large) 18.5±4.2 9.5±2.1 2.8±0.4*
Intestine (small) 25.4±6.1 13.6±1.6 6.2±0.3*
Kidney 44.3±8.7 16.1±2.3* 7.6±0.3*
Liver 71.6±18.7 59.3±12.4 27.2±4.7
Lung 21.0±4.7 8.3±1.6 5.5±0.5*
Muscle 1.7±0.4 1.0±0.2 0.8±0.1
Pancreas 52.2±11.5 36.7±2.5 23.2±2.7
Pituitary 23.6±0.5 16.7±4.6 10.7±3.4
Red blood cells 0.8±0.1 0.5±0.1* 0.6±0.0*
Spleen 26.3±2.6 16.0±3.2* 7.4±0.7**
Submandibular gland 38.1±7.6 32.3±0.5 21.6±2.6
Urine 4.6±2.4 13.5±7.8 1.9±0.4
Data are listed as mean±SEM. N=4 in all groups
*P<0.05, **P<0.01, ***P<0.005 (compared to baseline value)
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selectively occupies a subset of striatal D2Rs, a property
which could potentially account for some of the characteristics
of dopamine stabilizers. However, as cautioned by the au-
thors, firm conclusions concerning maximal occupancy could
not be drawn since a limited dose range was examined (for
safety reasons) and since the number of subjects was small.
Ekesbo et al. (1999) reported a 76 % displacement of 11C-
raclopride by continuous infusion of (−)-OSU6162
(3 mg/kg/h) in rhesus monkeys, suggesting that in nonhuman
primates, a large fraction of striatal D2Rs is accessible to (−)-
OSU6162, similar to rodents (Natesan et al. 2006). Our
microPET data suggest that D2Rs in rat brain are only occu-
pied by pridopidine at relatively high (60 mg/kg) doses.
Dopamine stabilizers show some characteristics which are
not usually associated with D2R ligands, such as pro-cognitive
actions in natural forgetting and scopolamine-induced amne-
sia (Nilsson and Carlsson 2013), neuroprotective effects in
in vitro and in vivo models of Huntington’s disease (Ruiz
et al. 2012; DiPardo et al. 2013), and increased social interac-
tion in the MK-801 rat model of social withdrawal in schizo-
phrenia (Rung et al. 2005). In this context, the substantial
occupancy of sigma-1R by pridopidine at 3 and 15 mg/kg,
as demonstrated in the present study, is of particular interest
since sigma-1R ligands have been shown to possess anti-
amnesic and neuroprotective actions, efficacy against negative
symptoms in schizophrenia, and positive modulatory effects
on NMDA receptor activity (Maurice and Su 2009; Hayashi
et al. 2011; van Waarde et al. 2011). If verified in a patient
population, the potentially disease-modifying neuroprotective
effects of pridopidine would be highly relevant for the treat-
ment of Huntington’s patients. Sigma-1R has generated much
attention as a target for neuroprotective treatment, and the
sigma-1R agonist PRE-084 was recently demonstrated to al-
leviate motor impairments and restore dopamine terminal den-
sity in 6-hydroxydopamine-lesioned mice, an effect which
was not observed in sigma-1R knockout animals (Francardo
et al. 2014). Finally, sigma-1R ligands have been reported to
attenuate the locomotor effects elicited by methamphetamine
(Matsumoto et al. 2008), which could explain the findings
reported by Natesan et al. (2006) and Svensson et al. (2009)
that the ability of pridopidine to inhibit amphetamine-induced
locomotion is more potent than that of (−)-OSU6162 and per-
sists in D2R knockout mice.
In conclusion, the present study confirms a selective pref-
erence of pridopidine for sigma-1Rs over D2Rs and demon-
strates that pridopidine, in vivo, occupies a large fraction of
sigma-1Rs at the lower end of its behaviorally and
neurochemically active dose range, while requiring higher
doses to produce significant D2R occupancy. Our findings
warrant further investigation of the role of sigma-1 receptors
in the behavioral and neuroprotective effects of dopamine sta-
bilizers and of pridopidine in particular. However, the phar-
macological characterization of sigma-1R-mediated effects
may prove challenging since the classification of sigma li-
gands into agonists and antagonists remains tentative. The
functional effects of sigma-1R ligands in different cellular
and subcellular contexts may even depend on the
heteromeric partners of sigma-1Rs. Furthermore, where-
as several prescribed CNS drugs are known to signifi-
cantly occupy sigma-1R at therapeutic doses, the rele-
vance of this occupancy for treatment response has not
yet been convincingly demonstrated. Future experiments
employing sigma-1R knockout animals, rather than a
pharmacological blocking approach, may yield more
easily interpretable data.
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